166386-81-8

Upstream product

• 65-49-6 4-Aminosalicylic acid 
• 18282-51-4 4-iodo-benzyl alcohol 
• 1257333-76-8 C₁₁H₁₅IOSi 
• 1257334-15-8 C₁₁H₁₇IOSi 
• 16870-28-3 4-iodosalicylic acid 
• 18179-39-0 methyl 4-iodosalicylate 

Downstream Products

• 71780-40-0 methyl 3-hydroxy-4-(hydroxymethyl)-benzoate 
• 1257333-86-0 C₁₁H₁₁IO₄ 
• 38170-02-4 4-iodosalicylaldehyde 
• 210037-23-3 (4-iodo-2-methoxyphenyl)methanol 
• 183153-31-3 2,2,2-Triphenyl-1-oxa-2λ⁵-phospha-indan-6-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Antioxidant properties in a non-polar environment of difluoromethyl bioisosteres of methyl hydroxycinnamates

Objectives Many natural antioxidants have poor pharmacokinetic properties that impair their therapeutic use. For hydroxycinnamic acids (HCAs) and other phenolic antioxidants, their major drawback is their low lipophilicity and a rapid metabolism. The difl

Iridium-catalyzed arene ortho -silylation by formal hydroxyl-directed C-H activation

A strategy for the ortho-silylation of aryl ketone, benzaldehyde, and benzyl alcohol derivatives has been developed in which a hydroxyl group formally serves as the directing element for Ir-catalyzed arene C-H bond activation. One-pot generation of a (hyd

FUSED HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

Polyaromatic heterocyclic compounds and pharmaceutical/cosmetic compositions comprised thereof

Novel pharmaceutically/cosmetically-active polyaromatic heterocyclic compounds have the structural formula (I): STR1 in which Z is a divalent radical selected from among --O--, --S-- or --Nr'-- and Ar is either a radical having the following structural fo

Synthesis and biological activities of new heterocyclic aromatic retinoids

A series of 3-aryl-2H-1-benzopyrancarboxylic acid derivatives was synthesized and evaluated as Retinoic Acid Receptor (RAR) agonists. By modifications of the 3-aryl group, we have obtained new retinoids exhibiting potent cellular differentiating activities and high affinities for RARs. Moreover, hydrogenation of the 2H-1-benzopyran ring led to the 3-(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl -naphthalen-2-yl)-3,4-dihydro-2H-1-benzopyran-7-yl carboxylic acid, characterized by a RARβ binding profile.